Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What should men know about prostate-specific antigen screening before giving informed consent?

E C Chan1, D P Sulmasy

  • 1Division of General Internal Medicine, University of Texas Health Sciences Center, Houston, USA.

The American Journal of Medicine
|November 11, 1998
PubMed
Summary

Experts and patients agree on some facts for prostate-specific antigen (PSA) screening informed consent. However, physicians often omit crucial details patients consider important for PSA testing decisions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

G-1-activated membrane estrogen receptors mediate increased contractility of the human myometrium.

Endocrinology·2011
Same author

Researchers' preferences and attitudes on ethical aspects of genomics research: a comparative study between the USA and Spain.

Journal of medical ethics·2009
Same author

Reverse haemolytic plaque assay study of corticotropin-releasing hormone and arginine vasopressin interaction in ovine corticotropes.

Journal of neuroendocrinology·2009
Same author

Desensitization of superfused isolated ovine anterior pituitary cells to human corticotropin-releasing factor.

Journal of neuroendocrinology·2009
Same author

Large Molecular Weight Immunoreactive Corticotrophin-Releasing Hormone has Bioactivity on Superfused Ovine Pituitary Cells.

Journal of neuroendocrinology·2009
Same author

Decision-making in patients with advanced cancer compared with amyotrophic lateral sclerosis.

Journal of medical ethics·2008

Area of Science:

  • Urology
  • Public Health
  • Medical Ethics

Background:

  • Prostate-specific antigen (PSA) screening is a controversial topic in urology.
  • Informed consent is recommended before PSA testing due to its debated benefits and risks.
  • Understanding patient and expert perspectives on essential screening facts is crucial.

Purpose of the Study:

  • To identify and compare the key facts that medical experts and patients believe are essential for informed consent regarding PSA screening.
  • To compare expert and patient consensus on what information should be disclosed before PSA testing.

Main Methods:

  • A Delphi panel of 12 national experts (urologists and non-urologists) was convened.
  • Six focus groups involving 48 individuals (couples, including screened and unscreened men) were conducted.
Keywords:
Empirical ApproachHealth Care and Public HealthProfessional Patient Relationship

Related Experiment Videos

  • Key facts were ranked, and findings were interpreted through multidisciplinary focus groups.

    • Main Results:

    • All participants agreed on disclosing potential false positive/negative results and the uncertainty of PSA screening reducing prostate cancer mortality.
    • Experts highlighted uncertain benefits of treating early-stage prostate cancer, while patients emphasized the test is a blood test and can cause anxiety.
    • Urologists noted prostate cancer's potential incurability at symptomatic stages; non-urologists mentioned asymptomatic detection. Screened couples noted earlier detection than digital rectal examination; unscreened couples noted PSA controversy.

    Conclusions:

    • Physicians and patients share common ground on essential information for PSA screening informed consent.
    • Physicians may not adequately emphasize certain facts that patients deem important.
    • Discrepancies in perceived importance of facts may stem from physician expertise and patient experience, informing better PSA screening consent processes.